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Background. Most orthopaedic units do not have a policy for reversal of anticoagulation in patients with hip fractures. The aim
of this study was to examine the current practice in a district general hospital and determine diﬀerence in the time to surgery, if
any, with cessation of warfarin versus cessation and treatment with vitamin K. Methods. A retrospective review of the case notes
between January 2005 and December 2008 identiﬁed 1797 patients with fracture neck of femur. Fifty seven (3.2%) patients were
on warfarin at the time of admission. Patients were divided into 2 groups (A and B). Group A patients (16/57; 28%) were treated
withcessationofwarfarinonlyandgroup Bpatients (41;72%) received pharmacologicaltherapy inaddition to stoppingwarfarin.
Time to surgery between the two groups was compared. Results. The mean INR on admissionwas 2.9 (range 1.7–6.5) and prior to
surgery 1.4 (range 1.0–2.1). Thirty eight patients received vitamin K only and 3 patients received fresh frozen plasma and vitamin
K.Theaveragetimetosurgery was4.4daysingroupAand2.4daysingroupB. Thediﬀerence wasstatisticallysigniﬁcant(P<. 01).
Conclusion.ReversalofhighINRisimportanttoavoidsigniﬁcantdelayinsurgery.Thereisaneedforanationalpolicyforreversing
warfarinanticoagulationinpatientswithhipfractures requiringsurgery.VitaminKissafeandeﬀective foranticoagulationreversal
in hip fracture patients.
1.Introduction
Approximately 1% of the UK population is on oral antico-
agulation with vitamin K antagonists [1]. Warfarin therapy
is commonly administered to elderly patients for conditions
such as atrial ﬁbrillation, prosthetic heart valves, and throm-
boembolic disorders [2]. This population group is prone
to osteoporotic fractures, such as fracture neck of femur.
Currentrecommendationsstatethatsurgeryforhipfractures
following patient optimisation should be undertaken early,
ideallywithin24–48hours[3–8].Thishascreatedachallenge
for orthopaedic surgeons as warfarin anticoagulation can
cause signiﬁcant delay in the surgical management of these
patients [9]. Reversal of anticoagulation to prevent excessive
bleeding at the time of hip surgery is required. This,
however, carries a risk of thromboembolism that is further
superimposed by immobility and hip surgery itself [10–12].
On the other hand, delaying surgery results in increased
morbidity and mortality [7]. Complications of recumbency
include pneumonia, pressure sores, muscle wasting, and
urinary tract infections [13].
In order to reverse anticoagulation, one can “wait and
watch” for INR to correct itself by stopping warfarin only, or
actively reverse anticoagulation using pharmacologic means.
These include vitamin K, fresh frozen plasma, clotting factor
concentrates, or a combination of these [14]. Studies have
shown that it may take up to 4 days for INR to reach
acceptable levels for surgery [15]. There is a lack of local and
national guidelinesfor reversal of anticoagulation in patients
with a hip fracture [16, 17]. This study examines the current
practice of perioperative management of anticoagulation in
hip fracture patients in a district general hospital setting.2 ISRN Hematology
2.PatientsandMethods
We retrospectively reviewed case notes of patients who un-
derwent surgery for fracture neck of femur between January
2005 and December 2008 at our unit. Patients on warfarin
were identiﬁed and evaluated. The clinical indication for
warfarin therapy, INR on admission and prior to surgery
were documented. Patients were divided into two groups.
Group A patients were treated with cessation of warfarin
only, and group B patients received pharmacological therapy
in addition to stopping warfarin. Time to surgery (excluding
any other reason for delay) between the two groups was
compared. Statistical analysis was done using one-way
analysis of variance (ANOVA) test.
3.Results
Between January 2005 and December 2008, 1797 patients
with fracture neck of femur underwent hip surgery in our
unit. Fifty-seven (3.2%) of these patients were on warfarin
therapy at the time of admission. The mean age was 79.3
years (range 58–99), and 34 (59.6%) were females. The
indications for warfarin treatment were as follows:
(i) atrial ﬁbrillation (AF), 40 patients (70.1%)
(ii) thromboembolism, 12 patients (21.1%)
(iii) prosthetic heart valves, 5 patients (8.8%).
The mean INR on admission was 2.9 (range 1.7–6.5)
and prior to surgery 1.4 (range 1.0–2.1). Thirty patients
(52.6%) had an extracapsular fracture; 28 were treated with
a dynamic hip screw (DHS) and 2 with an intramedullary
hip screw (IMHS). Twenty-seven patients (47.4%) had
intracapsular fracture neck of femur; 24 were treated
with a hemiarthroplasty and 3 with cannulated screws.
The method of anticoagulation reversal (watchful waiting
or pharmacologic) was decided by the admitting doctor,
the Orthopaedic Consultant, or following discussion with
the Haematology Consultant. High INR was managed by
watchful waiting in 16 (28.1%) and pharmacologic therapy
in 41 (71.9%) patients. Despite cessation of warfarin in the
watchful waiting group, INR initially increased in 5 patients
(8.8%). In the pharmacologic reversal group, 38 patients
received intravenous (IV) vitamin K (5–10mg) only, and 3
patients received fresh frozen plasma (FFP) and IV vitamin
K (5–10mg). Three patients who received FFP and vitamin
K had high INR values (5.2, 5.5, 6.5) on admission and were
discussed with the Haematology Consultant.
Reasons for surgical delay in warfarinised hip frac-
ture patients, other than INR, were obtained from the
notes. Seven patients in total had surgery delayed due to
reasons other than high INR. These included medically
unwell patients requiring optimization (4 patients); awaiting
echocardiogram (1 patients); awaiting pacemaker check (1
patient); awaiting further imaging to conﬁrm fracture (1
patient). These patients were excluded from our study. The
average time to surgery from admission in patients not given
pharmacologic treatment was 4.4 days (range 1–8 days).
The averagetime tosurgery fromadmission inpatientsgiven
pharmacologic treatment was 2.4 days (range 1–5 days). The
diﬀerence between the 2 groups is statistically signiﬁcant
(P<. 01).
4.Discussion
Most of the patients (71.9%) were managed using vitamin K
and waiting for the INR to reach acceptable levels for anaes-
thesia and surgery. Warfarin was stopped on admission for
all patients. A watch and wait policy was used for 16 patients
(28.1%). The lack of standard protocol resulted in patients
being given variable treatments to reverse anticoagulation.
The decision was generally dependent upon the INR level,
the indication for warfarin, and the urgency for surgery.
An interesting ﬁnding in 5 of our patients in the
“watch and wait” group was an increase in INR value one
day after admission. This was also observed in a study
investigating surgical delay in patients on warfarin [14].
T h ee r r a t i ci n c r e a s ei nI N Rw a st h o u g h tt ob es e c o n d a r y
to posttraumatic stress responses, immobilization, and long
periodsoffasting insurgicalpatients[14].Theadditiveeﬀect
of these factors on the anticoagulation eﬀect of warfarin has
also been demonstrated in an experimental study [18].
The mean INR on admission for our patients was 2.9
(range 1.7–6.5) and prior to surgery 1.4 (range 1.0–2.1).
There is a consensus that performing surgery in anti-
coagulated patients will increase the risk of intra- and
post operative bleeding despite adequate surgical technique
[19–21]. Current guidelines recommend an INR of less than
1.5 before any major surgery [22]. However, some surgeons
and anaesthetists still undertook hip fracture surgery with a
slightly higher level. Three patients were operated with INR
> 1.5, and two of them received intraoperative FFP. INR of
gr ea t erth a n1.5e xpos ess ur gi ca lpa ti en tst oi n cr ea s edri s ksof
intra- andpostoperativebleedingcomplications[19,23,24].
In addition, the type of anaesthesia may be aﬀected by
anticoagulation. Bleeding and neurological dysfunction may
occur during the insertion or removal of a spinal or epidural
catheter in an anticoagulated patient [25–27]. Warfarin
therapy is a contraindication for regional anaesthesia, such
as spinal and epidural [12].
The thromboembolic risk after discontinuing warfarin
should also be taken into consideration. This depends on
the clinical indication for warfarin, the period the patient
remains without anticoagulation therapy, the degree of
anticoagulation reversal, and the type of surgical procedure
undertaken [23, 24]. There are speciﬁc clinical indications
thatentail ahigh risk for thrombosis. These includemechan-
ical prosthetic heart valves and chronic atrial ﬁbrillation
in association with other stroke risk factors. The high-risk
group also includes patients with recent venous or arterial
thromboembolism within the preceding 3 weeks [28]. Lower
risk patientsarethosewithAFwithoutadditionalrisk factors
for stroke patients with deep vein thrombosis treated for
more than six months after the acute eventand patients with
a hypercoagulable state without a thrombotic complication
[28].Inthehigh-risk group,theabsoluteriskofthromboem-
bolism in a 6–8-day perioperative period when warfarinISRN Hematology 3
is interrupted is approximately 0.3%. This corresponds to
approximately 0.03% in the low-risk group [28].
The average time to surgery from admission in patients
in the “watch and wait” group was 4.4 days (range 1–8 days).
The averagetime tosurgery fromadmission inpatientsgiven
pharmacologic treatment was 2.4 days (range 1–5 days). The
diﬀerence between the 2 groups is statistically signiﬁcant
(P<. 01). These results have reinforced data obtained from
previous studies [9, 13, 14, 17, 29–31]. The ﬁndings of this
study revealed little evidence to support watchful waiting
as the best strategy in preventing delay for semiurgent
surgery. It is clear that pharmacologic reversal of warfarin
anticoagulation facilitates earlier surgery in patients with hip
fractures. It is costeﬀective, as it decreases hospital inpatient
stay [9]. There were no side eﬀects of pharmacologic
reversal in our study. Risks of intravenous and subcutaneous
vitamin K include anaphylactoid and cutaneous reactions
respectively. Recent studies have recommended oral vitamin
K for warfarin reversal [17, 29, 32, 33]. There is minimal
diﬀerence in postsurgery rewarfarinisation time following
low dose vitamin K administration in hip fracture patients
compared to “watch and wait” patients. This indicates few
discharge delays duetopostsurgery rewarfarinisation [9, 29].
There are no clear guidelines in the literature for
anticoagulation reversal in hip fracture patients. For elective
hip operations, most surgeons adopt a “wait and watch
policy.”Warfarin isgenerallydiscontinued 5 dayspriorto the
elective procedure for INR to become subtherapeutic [34].
In emergencies, such as young patients with hip fractures, a
rapidcorrectionofINRisrequired.Availableoptionsinclude
vitamin K, infusion of fresh frozen plasma, or prothrombin
complex concentrate. This depends on the INR level and the
urgency of surgical intervention. Warfarin acts as a vitamin
K antagonist and inhibits γ-carboxylation of coagulation
factors II, V, IX, and X, protein C, and protein S [35]. It
has a half-life of approximately 40h, and this may be further
increased in the elderly. In most patients with INR 2.0–
3.0, the level falls to less than 1.5 within 96–115h after the
last warfarin dose [15]. However, if the steady state of INR
is greater than 3.0, or the patient is elderly, more time is
r e q u i r e df o rt h el e v e lt of a l lt ol e s st h a n1 . 5[ 23].
Overanticoagulation can result from a multitude of
factors.Theseincludeadministration ofinappropriatelyhigh
warfarin doses, altered protein binding, decreased vitamin K
intake, reduced vitamin K synthesis, and increased clearance
of vitamin K-dependent clotting factors. Elderly hip fracture
patientsarefrequentlyonothermedications.Drugsthatalter
l i v e re n z y m ea c t i v i t yo rc o m p e t ew i t hw a r f a r i nf o rp r o t e i n
binding will also aﬀect the level of anticoagulation [36]. In
addition, anticoagulant responses can be aﬀected by various
factors such as age, body weight, gender, and ethnicity [37].
Vitamin K therapy alone is inappropriate if immediate
normalisation of the INR is required in hip fracture or
actively bleeding patients. This is because the onset of
action is 4–6h after intravenous administration and at least
24h after oral administration [34, 38]. High doses will
not further shorten the time to anticoagulation reversal.
However, high doses may lower INR more than is necessary
and cause warfarin resistance that persists for up to 1 week
[39]. Some authorities, such as the American College of
Cardiology/American Heart Association, suggest avoidance
of Vitamin K for patients with mechanical valves for fear of
valve thrombosis [40].
Fresh frozen plasma can reverse anticoagulation imme-
diately without causing any later resistance to warfarin or
heparin [41]. However, itseﬀect dissipates within 8–12h and
is optimally administered within 4h of the procedure [42].
Risks include anaphylactoid reactions, alloimmunisation,
excessive intravascular volume [42], and transmission of
infection [21]. In addition, italso mustbe thawed before use,
which can delay treatment.
Prothrombin complex concentrates (PCCs) contain high
concentrations of the coagulation factors inactivated by
warfarin, namely, factors II, VII, IX, and X, and can be
rapidly administered. There are no studies evaluating the use
of PCCs in hip fracture patients requiring anticoagulation
reversal. A major advantage of PCCs over FFP is that smaller
volumes of PCCs are required to reverse anticoagulation
[37]. PCCs are also quicker to prepare than FFP [38].
The time required for INR correction was reported to
be ﬁve times more rapid with PCCs than FFP [43]. One
important consideration is the association of FFP with a
risk of transfusion-related acute lung injury, which has
not been documented as a safety concern with PCCs [44].
However, the primary safety concern with PCCs has been
their association with thrombogenic events such as stroke,
myocardial infarction, pulmonary embolism, disseminated
intravascular coagulation, and deep vein thrombosis [45].
The majority of hip fracture patients do not require imme-
diate surgery. Therefore, the risks of administering PCCs
to reverse anticoagulation generally outweigh the beneﬁts.
Surgeons should, however, be aware of the availability of
PCCs for rapid anticoagulation reversal.
There are no guidelines for perioperative bridging ther-
apy for patients on long-term warfarin requiring surgery.
However, it is advocated that most patients except those at
the highest risk of thromboembolism, while oﬀ warfarin,
do not need bridging therapy. High-risk patients (e.g., with
mechanical prosthetic valves) are recommended to receive
unfractionated heparin whilst the INR is subtherapeutic
[46]. Discussion with the haematology and cardiology
departments is mandatory in this group of patients in order
to carefully manage their anticoagulation.
There were limitations of our study. Patients who were
not local to our area could not be included. This was
due to the fact that GP anticoagulation records were not
available.Therefore, notall warfarinised patientsundergoing
hip fracture surgery in our unit were included. As previ-
ously mentioned, not all surgeons and anaesthetists in our
unit required the INR to be strictly less than 1.5 before
undertaking the procedure. Another limitation is the lack
of randomisation and the retrospective analysis which make
this study liable for selection bias.
Previous studies have reported similar experience with
hip fracture patients on warfarin [9, 13, 14, 17]. Al-Rashid
et al. reviewed the literature and recommended that hip
fracture patients should be stratiﬁed into high- or low-
risk categories based on clinical indication for warfarin4 ISRN Hematology
and comorbidities [13]. Low-risk patients can be given
intravenous or oral Vitamin K until INR is below 1.5. For
high-risk patients requiring surgery immediately or on the
sameday,freshfrozenplasma shouldbeconsidered.Bridging
therapy with low molecular heparin should be used for
high risk patients for the duration of the subtherapeutic
INR.
5.Conclusion
This study conﬁrms the variation in practice for manage-
ment of hip fracture patients on warfarin needing semi-
urgent surgery. Reversal of warfarin anticoagulation facili-
tated earlier surgery. Patients on warfarin admitted with hip
fractures should have their anticoagulation reversed to avoid
signiﬁcant delays in surgery. Further prospective studies are
neededtoassess thebestmanagement ofwarfarin anticoagu-
lation in acute preoperative admissions through a combined
eﬀort from surgeons, haematologists, and cardiologists. A
national policy should be developed for reversing warfarin
anticoagulation in patients with hip fractures requiring
surgery. Current evidence favours the use of oral vitamin K
for anticoagulation reversal in hip fracture patients.
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